What Does Altri, SGPS, S.A.'s (ELI:ALTR) Share Price Indicate?

By
Simply Wall St
Published
July 05, 2021
ENXTLS:ALTR
Source: Shutterstock

Altri, SGPS, S.A. (ELI:ALTR), might not be a large cap stock, but it saw significant share price movement during recent months on the ENXTLS, rising to highs of €6.72 and falling to the lows of €5.24. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Altri SGPS' current trading price of €5.65 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Altri SGPS’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for Altri SGPS

What's the opportunity in Altri SGPS?

The stock seems fairly valued at the moment according to my valuation model. It’s trading around 11.92% above my intrinsic value, which means if you buy Altri SGPS today, you’d be paying a relatively fair price for it. And if you believe the company’s true value is €5.04, there’s only an insignificant downside when the price falls to its real value. Is there another opportunity to buy low in the future? Since Altri SGPS’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Can we expect growth from Altri SGPS?

earnings-and-revenue-growth
ENXTLS:ALTR Earnings and Revenue Growth July 6th 2021

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to more than double over the next couple of years, the future seems bright for Altri SGPS. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? It seems like the market has already priced in ALTR’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping an eye on ALTR, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example, we've discovered 3 warning signs that you should run your eye over to get a better picture of Altri SGPS.

If you are no longer interested in Altri SGPS, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

If you’re looking to trade a wide range of investments, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.